Thyroid hormones and growth in health and disease

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 3, Issue 2, 2011, Pages 51-55

  Tanm, Ömer ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Children conflict of interest: none declared; Growth; Thyroid

Indexed keywords

IODIDE PEROXIDASE; PROTIRELIN; PROTIRELIN RECEPTOR; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROTROPIN; THYROTROPIN RECEPTOR;

CHILD; CHILD GROWTH; CHILDHOOD DISEASE; CHRONIC DISEASE; GROWTH RETARDATION; HUMAN; NEGATIVE FEEDBACK; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SYSTEMIC DISEASE; THYROID HORMONE BLOOD LEVEL;

CHILD; GROWTH; GROWTH DISORDERS; HUMANS; HYPOTHYROIDISM; KIDNEY DISEASES; LIVER DISEASES; MALNUTRITION; MENTAL DISORDERS; OBESITY; THYROID HORMONES;

EID: 79959256520     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/jcrpe.v3i2.11     Document Type: Review

References (71)

1. Tarim O. Abnormal endocrine test results due to non-endocrine condirtions. In: Lifshitz F (ed). Pediatric Endocrinology. 5th edition. Informa Health Care, NY, London,2007; 581-595.
2. Liu Z, Long W, Fryburg DA, Barrett EJ. The Regulation of Body and Skeletal Muscle Protein Metabolism by Hormones and Amino Acids. J Nutr 2006;136:212-217.
3. Dickhoff WW, Brown CL, Sullivan CV, Bern HA. Fish and amphibian models for developmental endocrinology. J Exp Zool Suppl 1990;4:90-97.
4. Kikuyama S, Kawamura K, Tamaka S, Yamamoto K. Aspects of amphibian morphogenesis: hormonal control. Int Rev Cytol 1993;145:105-148.
5. Tata JR. Amphibian metamorphosis as a model for the developmental actions of thyroid hormones. Mol Cell Endocrinol 2006;246:10-20.
6. Su Y, Damjanovski S, Shi Y, Shi YB. Molecular and cellular basis of tissue remodeling during amphibian metamorphosis. Histol Histopathol 1999;14:175-183.
7. Francavilla A, Carr BI, Azzarone A, Polimeno L, Wang Z, Van Thiel DH, Subbotin V, Prelich JG, Starzl TE. Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. Hepatology 1994;20:1237-1241.
8. Malik R, Mellor N, Selden C, Hodgson H. Triiodothyronine enhances the regenerative capacity of the liver following partial hepatectomy. Hepatology 2003;37:79-86.
9. Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology 2005;146:4425-4430.
10. Di Fulvio M, Coleoni AH, Pellizas CG, Masini-Repiso AM. Tri-iodothyronine induces proliferation in cultured bovine thyroid cells: evidence for the involvement of epidermal growth factor-associated tyrosine kinase activity. J Endocrinol 2000;166:173-182.
11. Foster MP, Montecino-Rodriguez E, Dorshkind K. Proliferation of bone marrow pro-B cells is dependent on stimulation by the pituitary/thyroid axis. J Immunol 1999;163:5883-5890.
12. Ohmura T, Katyal SL, Locker J, Ledda-Columbano GM, Columbano A, Shinozuka H. Induction of cellular DNA synthesis in the pancreas and kidneys of rats by peroxisome proliferators, 9-cis retinoic acid, and 3,3', 5-triiodo-L-thyronine. Cancer Res 1997;57:795-798.
13. Ledda-Columbano GM, Perra A, Pibiri M, Molotzu F, Columbano A. Induction of pancreatic acinar cell proliferation by thyroid hormone. J Endocrino 2005;185:393-399.
14. Archavachotikul K, Ciccone TJ, Chinoy MR, Nielsen HC, Volpe MV. Thyroid hormone affects embryonic mouse lung branching morphogenesis and cellular differentiation. Am J Physiol Lung Cell Mol Physiol 2002;282:359-369.
15. Kassem M, Mosekilde L, Eriksen EF. Effects of triiodothyronine on DNA synthesis and differentiation markers of normal human osteoblast-like cells in vitro. Biochem Mol Biol Int 1993;30:779-788.
16. Baas D, Bourbeau D, Sarlieve LL, Ittel ME, Dussault JH, Puymirat J. Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone. Glia 1997;19:324-332.
17. Garcia-Silva S, Perez-Juste G, Aranda A. Cell cycle control by the thyroid hormone in neuroblastoma cells. Toxicology 2002;181-182:179-182.
18. Bauer A, Mikulits W, Lagger G, Stengl G, Brosch G, Beug H. The thyroid hormone receptor functions as a ligand-operated developmental switch between proliferation and differentiation of erythroid progenitors. EMBO J 1998;17:4291-4303.
19. Huang YH, Tsai MM, Lin KH. Thyroid Hormone Dependent Regulation of Target Genes and Their Physiological Significance. Chang Gung Med J 2008;31:325-334.
20. Cheng SY. Isoform-dependent actions of thyroid hormone nuclear receptors: lessons from knocking mutant mice. Steroids 2005;70:450-454.
21. Chen SL, Chang YJ, Wu YH, Lin KH. Mitogen-activated protein kinases potentiate thyroid hormone receptor transcriptional activity by stabilizing its protein. Endocrinology 2003;144:1407-1419.
22. Lin HY, Hopkins R, Cao HJ, Tang HY, Alexander C, Davis FB, Davis PJ. Acetylation of nuclear hormone receptor superfamily members: thyroid hormone causes acetylation of its own receptor by a mitogen-activated protein kinase-dependent mechanism. Steroids 2005;70:444-449.
23. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 2001;11:33-38.
24. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 2004;11:126-143.
25. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-457.
26. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-1357.
27. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:38-89.
28. Zavacki AM, Ying H, Christoffolete MA, Aerts G, So E, Harney JW, Cheng SY, Larsen PR, Bianco AC. Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology 2005;146:1568-1575.
29. Germain DLS, Galton VA, and Hernandez A. Defining the Roles of the Iodothyronine Deiodinases: Current Concepts and Challenges. Endocrinology 2009;150:1097-1107.
30. Peeters R, Fekete C, Goncalves C, Legradi G, Tu HM, Harney JW, Bianco AC, Lechan RM, Larsen PR. Regional physiological adaptation of the central nervous system deiodinases to iodine deficiency. Am J Physiol 2001;281:54-61.
31. Escobar-Morreale HF, Obregon MJ, Hernandez A, Escobar del Rey F, Morreale de Escobar G. Regulation of iodothyronine deiodinase activity as studied in thyroidectomized rats infused with thyroxine or triiodothyronine. Endocrinology 1997;138:2559-2568.
32. van Doorn J, Roelfsema F, van der Heide D. Conversion of thyroxine to 3,5,3?-triiodothyronine in several rat tissues in vivo: the effect of hypothyroidism. Acta Endocrinol (Copenh) 1986;113:59-64.
33. Beech SG, Walker SW, Arthur JR, Lee D, Beckett GJ. Differential control of type-I iodothyronine deiodinase expression by the activation of the cyclic AMP and phosphoinositol signalling pathways in cultured human thyrocytes. J Mol Endocrinol 1995;14:171-177.
34. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002;56:655-669.
35. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999;84:1311-1323.
36. DeGroot LJ. Nonthyroidal illness syndrome. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 5th ed. Philadelphia: Elsevier; 2006;2101-2112.
37. Kmiec Z, Kotlarz G, Smiechowska B, Mysiwski A. Thyroid hormones homeostasis in rats refed after short-term and prolonged fasting. J Endocrinol Invest 1996;19:304-311.
38. Boelen A, Wiersinga WM, Fliers E. Fasting-induced changes in the hypothalamus-pituitary-thyroid axis. Thyroid 2008;18:123-129.
39. Wells S, Campbell R. Decrease in resting metabolic rate during rapid weight loss is reversed by low dose thyroid hormone treatment. Metabolism 1986;35:291-298.
40. Forsum E, Hillman PE, Nesheim MC. Effect of energy restriction on total heat production, basal metabolic rate, and specific dynamic action of food in rats. J Nutr 1981;111:1691-1697.
41. Chopra IJ. Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 1997;82:329-334.
42. O'Mara BA, Dittrich W, Lauterio TJ, St Germain DL. Pretranslational regulation of type I 5?-deiodinase by thyroid hormones and in fasted and diabetic rats. Endocrinology 1993;133:1715-1723.
43. Debaveye Y, Ellger B, Mebis L, Darras VM, Van den Berghe G. Regulation of tissue iodothyronine deiodinase activity in a model of prolonged critical illness. Thyroid 2008;18:551-560.
44. Debaveye Y, Ellger B, Mebis L, Visser TJ, Darras VM, Van den Berghe G. Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits. Endocrinology 2008;149:4218-4228.
45. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab 2008;4:148-155.
46. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J, Engel FB, Obregon MJ, Larsen PR, Bianco AC, Huang SA. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 2008;118:975-983.
47. Lamirand A, Pallud-Mothre S, Ramauge M, Pierre M, Courtin F. Oxidative stress regulates type 3 deiodinase and type 2 deiodinase in cultured rat astrocytes. Endocrinology 2008;149:3713-3721.
48. Kandemir N, Yordam N. Height prognosis in children with late-diagnosed congenital hypothyroidism. Turk J Pediatr 2001;43:303-306.
49. Massa G, de Zegher F, Dooms L, Vanderschueren-Lodeweyckx M. Hyperthyroidism accelerates growth in Turner syndrome. Acta Paediatr 1992;81:362-364.
50. Esposito S, Prange AJ, Golden RN. The thyroid axis and mood disorders: overview and future prospects. Psychopharmacol Bull 1997;33:205-217.
51. Joffe RT, Levitt AJ. The thyroid and depression. In: Joffe RT, Levitt AJ, eds. The Thyroid Axis and Psychiatric Illness. Washington: American Psychiatric Press, 1993;195-217.
52. Levine RL. Endocrine aspects of eating disorders in adolescents. Adolesc Med 2002;13:129-143.
53. Vigersky RA, Loriaux DL, Andersen AE, Lipsett MB. Anorexia nervosa, behavioural and hypothalamic aspects. Clin Endocrinol Metab 1976;5:517-535.
54. Bereket A, Turan S, Karaman MG, Haklar G, Özbay F, Yazgan MY. Height, weight, IGF-1, IGFBP-3, and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Horm Res 2005;63:159-164.
55. Ross DS, Daniels GH, Dienstag JL, Ridgway EC. Elevated thyroxine levels due to increased thyroxine binding globulin in acute hepatitis. Am J Med 1983;74:564-569.
56. Schussler GC, Schaffner F, Korn F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med 1978;299:510-515.
57. Gardner DF, Carithers RL, Utiger RD. Thyroid function tests in patients with acute and resolved hepatitis B virus infection. Ann Intern Med 1982;96:450-452.
58. Hepner GW, Chopra IJ. Serum thyroid hormone levels in patients with liver disease. Arch Intern Med 1979;139:1117-1120.
59. Kano T, Kojima T, Takahashi T, Muto Y. Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices. Gastroenterol Jpn 1987;22:344-353.
60. Cooper DS, Daniels GH, Ladenson PW, Ridgway EC. Hyperthyroxinemia in patients treated with high dose propranolol. Ann J Med 1982;73:867-871.
61. Felicetta JV, Green WL, Nelp WB. Inhibitoin of hepatic binding of thyroxine by cholesystographic agents. J Clin Invest 1980;65:1032-1040.
62. Mooradian AD, Morley JE. Endocrine dysfunction in chronic renal failure. Arch Intern Med 1984;144:351-353.
63. Mooradian AD, Morley JE, Korchik WK, Ma D, Shafer RB. Iodine trapping and organification in patients with chronic renal failure. Eur J Nucl Med 1983;8:495-498.
64. Hardy MJ, Ragbeer SS, Nascimento L. Pituitary thyroid function in chronic renal failure assessed y a highly sensitive thyrotropin assay. J Clin Endocrinol Metab 1988;66:233-236.
65. Komaki G, Tamai H, Kiyohara K, Fukino O, Nakagawa T, Mori S, Kumagai LF, Nagataki S. Changes in the hypothalamic-pituitary-thyroid axis during acute starvation in non-obese patients. Endocrinol Jpn 1986;33:303-308.
66. Danforth E Jr, Burger AG. The impact of nutrition on thyroid hormone physiology and action. Annu Rev Nutr 1989;9:201-227.
67. Pugliese M, Lifshitz F, Fort P, Recker B, Ginsberg L. Pituitary-hypothalamic response in adolescents with growth failure due to fear of obesity. J Am Coll Nutr 1987;6:113-120.
68. de Rosa G, Della Casa S, Corsello SM, Ruffilli MP, de Rosa E, Pasargiklian E. Thyroid function in altered nutritional state. Exp Clin Endocrinol 1983;82:173-177.
69. Burman KD, Lukes Y, Wright FD, Wartofsky L. Reduction in hepatic triiodothyronine binding capacity induced by fasting. Endocrinology 1977;101:1331-1334.
70. Alemzadeh R, Lifshitz F. Childhood obesity. In: Lifshitz F, ed. Pediatric Endocrinology. New York: Marcel Dekker, 1996;753-774.
71. Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, Ovesen L, Jørgensen T. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019-4024.